Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer

Bounaix Morand du Puch, Christophe; Nouaille, Michelle; Giraud, Stéphanie; Labrunie, Anaïs; Luce, Sandrine; Preux, Pierre-Marie; Labrousse, François; Gainant, Alain; Tubiana-Mathieu, Nicole; Le Brun-Ly, Valérie; Valleix, Denis; Guillaudeau, Angélique; Mesturoux, Laura; Coulibaly, Béma; Lautrette, Christophe; Mathonnet, Muriel

doi:10.1186/s12967-016-0765-4

Journal of Translational Medicine

Table 2 Treatments and clinical responses of advanced CRC patients included in the pilot trial

From: Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer

Subject ID	First cure Results of first evaluation	Second cure Results of second evaluation	Third cure Results of third evaluation	Survival time (months) at end of study
01^a	5-FU + Radiotherapy Disease progression	8 C FOLFIRI Disease progression	1 C 5-FU Disease progression	27
02	4 C FOLFOX Stable disease	4 C FOLFOX Stable disease	4 C FOLFOX Complete response	31
03^a	1 C 5-FU Disease progression	4 C Panitumumab Disease progression	– Disease progression	08
04^a	4 C FOLFOX + Bevacizumab Partial response	4 C FOLFOX + Bevacizumab Stable disease	4 C Bevacizumab Disease progression	21
05^b	6 C FOLFOX + Bevacizumab Stable disease	4 C FOLFOX + Bevacizumab Disease progression	Bevacizumab Disease progression	25
06^b	4 C FOLFIRI + Bevacizumab Stable disease	4 C FOLFIRI + Bevacizumab Stable disease	4 C Bevacizumab Disease progression	24
07	3 C 5-FU Stable disease	4 C 5-FU Stable disease	1 C 5-FU Complete response	24
08	3 C FOLFOX Stable disease	4 C FOLFOX Disease progression	4 FOLFIRI Disease progression	31
09^a,b	4 C FOLFOX Disease progression	4 C FOLFIRI + Bevacizumab Stable disease	4 C FOLFIRI Stable disease	14
10	8 C FOLFOX Stable disease	4 C FOLFOX Stable disease	N/A Stable disease	17
11	3 C 5-FU Stable disease	N/A Stable disease	N/A Stable disease	16
12	4 C FOLFIRI + Bevacizumab Stable disease	4 C FOLFIRI + Bevacizumab Partial response	4 C Bevacizumab Stable disease	15
13	3 C 5-FU Stable disease	2 C 5-FU Stable disease	2 C 5-FU Stable disease	15
14	8 C FOLFOX Stable disease	4 C 5-FU + Folinic acid Stable disease	N/A Stable disease	15
15	4 C FOLFOX + Bevacizumab Partial response	9 C FOLFOX + Bevacizumab Stable disease	N/A Partial response	14
16	6 C FOLFOX Stable disease	4 C FOLFOX Stable disease	4 C FOLFOX Stable disease	14
17	7 C FOLFOX + Bevacizumab Disease progression	5 C FOLFOX + Bevacizumab Stable disease	N/A Stable disease	14
18	4 C FOLFOX Partial response	5 C FOLFOX + Bevacizumab Partial response	N/A Partial response	14
19	3 C 5-FU Stable disease	3 C 5-FU Stable disease	3 C 5-FU Disease progression	13

Chemotherapy regimens received by each patient during the course of their treatment, and ensuing clinical outcome (disease progression, stabilization, partial or complete response) determined through three consecutive evaluations. Survival time at completion of study is also provided
^aPatient died before end of study as a result of CRC progression
^bReceived pre- and or per-surgery chemotherapy

Back to article page

ISSN: 1479-5876

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com